hotspot -WSS

hotspot

author：focus 2025-09-30 13:13:54 - browse：35

Beth Israel Deaconess Medical Center in Boston — David L. Ryan/The Boston Globe

Steward Health Care’s Massachusetts hospitals are on the brink of financial disaster. But in many important ways, Steward’s troubles are just a symptom of a larger crisis engulfing the entire industry.

While Steward’s for-profit ownership structure put its hospitals at a disadvantage, many health care executives say the state’s entire network of hospitals is approaching a capacity shortage not seen since the early days of the Covid-19 pandemic.

Industry leaders are calling for urgent action from the Healey administration and the Legislature to help stem the crisis. Even just simplifying the state regulatory bureaucracy and approvals for bringing uninsured patients into the MassHealth system would help, executives say.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA needs staff influx to meet gene therapy needs, Marks says

focus

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Patients' immediate access to test results puts radiologists in a bind

Senate HELP committee spars over health care workforce policies

CommonSpirit Health keeps growing, even as it loses money

Pregnancy discrimination could be enabled by AI

Patients' immediate access to test results puts radiologists in a bind

leisure time

hotspot

focus

The high cost of giving birth even with insurance

CMS should re

Alkermes shareholders re

FDA approves world's first CRISPR

As demand for Covid shots wanes, Moderna seeks its next success

Intarcia’s device

What does generative AI mean for health care? We asked experts

EpiPen alternative approval delay highlights citizen petition issue

Malaria cases in Florida and Texas: Here’s what you need to know

Pregnancy discrimination could be enabled by AI

hotspot

Spinal cord stimulation reduces pain in amputees, study finds

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

What causes an itch? Researchers may have solved the mystery

Roche to buy Carmot Therapeutics, developer of obesity drugs

Changes to biosimilar regulatory framework must prioritize patients

Intarcia’s device

knowledge

entertainment

knowledge

Wikipedia